Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $73.37, but opened at $75.22. Korro Bio shares last traded at $73.99, with a volume of 763 shares traded.
Wall Street Analysts Forecast Growth
KRRO has been the subject of a number of analyst reports. Royal Bank of Canada boosted their price target on Korro Bio from $70.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 27th. HC Wainwright boosted their price target on Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Piper Sandler restated an “overweight” rating and issued a $180.00 price objective on shares of Korro Bio in a report on Wednesday, March 27th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $120.00 price objective on shares of Korro Bio in a report on Tuesday, March 26th.
Read Our Latest Stock Report on KRRO
Korro Bio Stock Performance
Institutional Investors Weigh In On Korro Bio
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Korro Bio during the fourth quarter worth $53,648,000. Eventide Asset Management LLC acquired a new position in Korro Bio during the fourth quarter valued at $26,185,000. 72 Investment Holdings LLC acquired a new position in Korro Bio during the fourth quarter valued at $13,269,000. Vanguard Group Inc. acquired a new position in Korro Bio during the fourth quarter valued at $12,988,000. Finally, Point72 Asset Management L.P. acquired a new position in Korro Bio during the fourth quarter valued at $12,741,000. 13.18% of the stock is owned by institutional investors and hedge funds.
Korro Bio Company Profile
Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Korro Bio
- There Are Different Types of Stock To Invest In
- Abbott Laboratories Outlook is Healthy: Buy the Dip
- What is the Australian Securities Exchange (ASX)
- ASML Fires Warning Shot For Tech Investors
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Prologis Stock Leading U.S. Logistics Boom
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.